Last reviewed · How we verify
Gemcitabine plus carboplatin
Gemcitabine plus carboplatin is a Small molecule drug developed by Chinese Society of Lung Cancer. It is currently in Phase 2 development. Also known as: Gemzar(Gemcitabine), Gemzar, Paraplatin.
At a glance
| Generic name | Gemcitabine plus carboplatin |
|---|---|
| Also known as | Gemzar(Gemcitabine), Gemzar, Paraplatin |
| Sponsor | Chinese Society of Lung Cancer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine plus carboplatin CI brief — competitive landscape report
- Gemcitabine plus carboplatin updates RSS · CI watch RSS
- Chinese Society of Lung Cancer portfolio CI
Frequently asked questions about Gemcitabine plus carboplatin
What is Gemcitabine plus carboplatin?
Gemcitabine plus carboplatin is a Small molecule drug developed by Chinese Society of Lung Cancer.
Who makes Gemcitabine plus carboplatin?
Gemcitabine plus carboplatin is developed by Chinese Society of Lung Cancer (see full Chinese Society of Lung Cancer pipeline at /company/chinese-society-of-lung-cancer).
Is Gemcitabine plus carboplatin also known as anything else?
Gemcitabine plus carboplatin is also known as Gemzar(Gemcitabine), Gemzar, Paraplatin.
What development phase is Gemcitabine plus carboplatin in?
Gemcitabine plus carboplatin is in Phase 2.
Related
- Manufacturer: Chinese Society of Lung Cancer — full pipeline
- Also known as: Gemzar(Gemcitabine), Gemzar, Paraplatin
- Compare: Gemcitabine plus carboplatin vs similar drugs
- Pricing: Gemcitabine plus carboplatin cost, discount & access